Cochlear

Seer is a medical technology company based in Melbourne, Victoria, focused on the diagnosis and management of neurological conditions, particularly epilepsy. Founded in 2016, Seer develops wearable devices integrated with cloud computing technology that enables hospital-standard monitoring and diagnosis in a home setting. The application not only tracks epilepsy but also monitors cardiac diseases and sleep patterns, capturing medical events through a mobile device. By utilizing machine learning systems, Seer provides patients with personalized insights, predictions, and alerts, helping them understand long-term illness patterns and enhancing their overall healthcare experience.

Nyxoah S.A. is a health-technology company based in Mont-Saint-Guibert, Belgium, focused on developing innovative solutions for treating sleep-disordered breathing, particularly obstructive sleep apnea (OSA). Founded in 2009, Nyxoah has created the Genio system, a CE-Mark validated bilateral neuro-stimulation therapy designed for patients with moderate to severe OSA. The company aims to improve the quality of life for OSA sufferers by offering a less cumbersome alternative to traditional devices and complex surgeries. Its technology features a tiny, battery-less implantable neurostimulator that targets the nerves of the tongue to prevent airway blockage, stimulating the muscles only when necessary. This approach not only reduces costs and simplifies implantation but also minimizes the risk of device migration. By collaborating with leading experts in sleep disorders, Nyxoah is dedicated to advancing neurostimulation devices that can significantly enhance the lives of those affected by OSA.

Nyxoah S.A. is a health-technology company based in Mont-Saint-Guibert, Belgium, focused on developing innovative solutions for treating sleep-disordered breathing, particularly obstructive sleep apnea (OSA). Founded in 2009, Nyxoah has created the Genio system, a CE-Mark validated bilateral neuro-stimulation therapy designed for patients with moderate to severe OSA. The company aims to improve the quality of life for OSA sufferers by offering a less cumbersome alternative to traditional devices and complex surgeries. Its technology features a tiny, battery-less implantable neurostimulator that targets the nerves of the tongue to prevent airway blockage, stimulating the muscles only when necessary. This approach not only reduces costs and simplifies implantation but also minimizes the risk of device migration. By collaborating with leading experts in sleep disorders, Nyxoah is dedicated to advancing neurostimulation devices that can significantly enhance the lives of those affected by OSA.

Earlens is a privately held medical technology company committed to transforming the hearing experience for millions of people who suffer from hearing loss.The company has developed the Earlens Contact Hearing Solution, which directly activates natural hearing, delivering the broadest bandwidth available today and superior sound quality. This revolutionary, non-surgical hearing solution uses a small lens to vibrate the eardrum, replicating the natural hearing process. The Earlens Contact Hearing Solution received FDA clearance in 2019 for a second generation of the Earlens technology. Unlike traditional hearing aids, which are in effect tiny speakers that simply turn up the volume on air conducted sound, the Earlens Contact Hearing Solution™ is the world’s first to deliver sound directly to the eardrum.

Developer of audiology practice management software designed to serve hearing care clinics. The company offers a cloud-based audiology software that integrates many services including patient clinical data, financing, reimbursement and marketing campaigns as well as front and back office operations, enabling hearing professionals to spend more time with their patients and less time on administrative overhead.

Earlens is a privately held medical technology company committed to transforming the hearing experience for millions of people who suffer from hearing loss.The company has developed the Earlens Contact Hearing Solution, which directly activates natural hearing, delivering the broadest bandwidth available today and superior sound quality. This revolutionary, non-surgical hearing solution uses a small lens to vibrate the eardrum, replicating the natural hearing process. The Earlens Contact Hearing Solution received FDA clearance in 2019 for a second generation of the Earlens technology. Unlike traditional hearing aids, which are in effect tiny speakers that simply turn up the volume on air conducted sound, the Earlens Contact Hearing Solution™ is the world’s first to deliver sound directly to the eardrum.

Otologics, LLC, a medical device company, develops and manufactures amplification products that are designed to improve communication of life for individuals with hearing loss. It offers Carina, an implantable treatment option for hearing loss. The company was founded in 1996 and is headquartered in Boulder, Colorado.

Cochlear Bone Anchored Solutions manufactures, and sells medical systems for hearing and facial rehabilitation.